Theranostic potential of biodegradable polymeric nanoparticles with paclitaxel and curcumin against breast carcinoma

Kim, Kyu Ri; You, Su Jung; Kim, Hyun Joo; Yang, Dae Hyeok; Chun, Heung Jae; Lee, Dongwon; Khang, Gilson

doi:10.1039/d1bm00370d

Cited by 18 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the CI values were even lower for PLGA-CUR-PTX nanoparticles, with 0.17 on 4T1 cells and 0.20 on MCF-7 cells, which demonstrated the good synergistic antitumor effect of CUR and PTX. Moreover, CUR and PTX coloaded PLGA nanoparticles had the lowest IC 50 values on 4T1 (CUR: 123.7 ng/mL; PTX: 66.7 ng/mL) and MCF-7 (CUR: 109.9 ng/mL; PTX: 59.37 ng/mL) cells, which were similar with the previous report . In this study, CUR combined with PTX could decline the IC 50 of both CUR and PTX.…”

Section: Resultsmentioning

confidence: 99%

Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity

Liao

et al. 2022

ACS Omega

View full text Add to dashboard Cite

Codelivery of chemotherapeutic drugs in nanoparticles can enhance the therapeutic effects against tumors. However, their anticancer properties and physiochemical characteristics can be severely influenced by many formulation parameters during the preparation process. It is a complicated development phase to select the optimal parameters for preparation of nanoparticles based on the commonly used one single parameter method, which consumes a lot of money, time, and effort, and sometimes even fails. Therefore, the statistical analysis based on Box−Behnken design (BBD) has attracted much attention in bioengineering fields because it can illustrate the influence of parameters, build mathematical models, and predict the optimal combinational factors in a decreased number of experiments. In this study, we used a three-factor three-level BBD design to optimize the preparation of poly(lactic-co-glycolic acid) (PLGA) nanoparticles coloaded with two anticancer drugs curcumin and paclitaxel (PLGA-CUR-PTX nanoparticles). The surfactant concentration, polymer concentration, and oil−water ratio were selected as independent variables. An optimized model of the formulation for PLGA-CUR-PTX nanoparticles was validated. The optimal nanoparticles possessed a uniform spherical shape, with an average size of 99.94 nm, and the drug encapsulation efficiencies of CUR and PTX were 63.53 and 80.64%, respectively. The drug release from nanoparticles showed a biphasic release behavior, with a release mechanism via diffusion and fundamentally quasi-Fickian diffusion. The optimized nanoparticles demonstrated an enhanced cytotoxicity effect with lower IC 50 values to 4T1 and MCF-7 breast cancer cell lines compared to free drugs. In summary, BBD optimization of CUR and PTX coloaded nanoparticles yielded a favorable drug carrier that holds potential as an alternative treatment for anticancer therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity

Liao

et al. 2022

ACS Omega

View full text Add to dashboard Cite

show abstract

“…The mean diameter and polydispersity index (PDI) of micelles formed in hydrogel precursor solutions were characterized by DLS (Zetasizer Nano ZS; Malvern Instruments, Malvern, UK) 55 . A specific concentration of solution (2 mg/mL) was immersed in Polystyrene Disposable Cells (Q-VETTES Semi-micro; Ratiolab, Frankfurt, Germany) and measured at 25 °C.…”

Section: Methodsmentioning

confidence: 99%

In-situ forming injectable GFOGER-conjugated BMSCs-laden hydrogels for osteochondral regeneration

Yang

You

et al. 2023

npj Regen Med

Self Cite

View full text Add to dashboard Cite

The collagen-mimetic peptide GFOGER possesses the chondrogenic potential and has been used as a cell adhesion peptide or chondrogenic inducer. Here, we prepared an injectable in situ forming composite hydrogel system comprising methoxy polyethylene glycol-b-polycaprolactone (MPEG-PCL) and GFOGER-conjugated PEG-PCL (GFOGER-PEG-PCL) with various GFOGER concentrations based on our recently patented technology. The conjugation of GFOGER to PEG-PCL was confirmed by 1H NMR, and the particle size distribution and rheological properties for the sol-gel transition behavior of the samples with respect to the GFOGER content were evaluated systemically. In vitro experiments using rat bone marrow-derived mesenchymal stem cells (BMSCs) revealed that the GFOGER-PEG-PCL hydrogel significantly enhanced expression of integrins (β1, α2, and α11), increased expression of FAK, and induced downstream signaling of ERK and p38. Overexpression of chondrogenic markers suggested that BMSCs have the potential to differentiate into chondrogenic lineages within GFOGER-PEG-PCL samples. In vivo studies using a rat osteochondral defect model revealed that transplanted BMSCs with GFOGER0.8-PEG-PCL survived at the defect with strong chondrogenic expression after 4 weeks. The stem cell-laden GFOGER0.8-PEG-PCL hydrogel produced remarkable osteochondral regeneration at 8 weeks of transplantation, as determined by histological findings and micro-CT analysis. The histomorphological score in the GFOGER0.8-PEG-PCL + BMSCs group was ~1.7-, 2.6-, and 5.3-fold higher than that in the GFOGER0.8-PEG-PCL, MPEG-PCL, and defect groups, respectively. Taken together, these results provide an important platform for further advanced GFOGER-based stem cell research for osteochondral repair.

show abstract

“…4T1 tumor-bearing mice were used to evaluate the anti-tumor efficacy of Cur@HFn in vivo (Kim et al., 2021 ; Yu et al., 2021 ). Female mice were inoculated with a suspension of 4T1 cells in physiological saline (100 μL, 1 × 10 6 cells) into the right mammary gland.…”

Section: Methodsmentioning

confidence: 99%

“…In recent years, a plethora of cytotoxicity and animal experiments have shown that Cur has good anti-cancer activity, especially in the treatment of breast cancer, prostate cancer, lung cancer, and ovarian cancer (Ma et al., 2019 ). Its mechanism is to inhibit P-gp and down-regulate nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathways, inducing apoptosis by suppressing the growth of cancer cells (Kim et al., 2021 ). Clinical trials have proved that Cur has few side effects and high safety, and the safe dose can be as high as 12 g per day (Kumari et al., 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Selective delivery of curcumin to breast cancer cells by self-targeting apoferritin nanocages with pH-responsive and low toxicity

Wang

Yin

et al. 2022

Drug Delivery

View full text Add to dashboard Cite

Breast cancer is prevalent and diverse with significantly high incidence and mortality rates. Curcumin (Cur), a polyphenol component of turmeric, has been widely recognized as having strong anti-breast cancer activity. However, its anti-cancer efficiency is largely impaired by some of its concomitant negative properties, including its poor solubility, low cellular uptake, and severe reported side effects. Hence, the necessity arises to develop a novel low-toxic and high-efficiency targeting drug delivery system (DDS). In this study, we developed a pH-sensitive tumor self-targeting DDS (Cur@HFn) based on self-assembled HFn loaded with Cur, in which Cur was encapsulated into HFn cavity by using a disassembly/reassembly strategy, and the Cur@HFn was characterized by ultraviolet–visible (UV–vis), dynamic light scattering (DLS), and transmission electron microscope (TEM). A variety of breast cancer cell models were built to evaluate cytotoxicity, apoptosis, targeting properties, and uptake mechanism of the Cur@HFn. The pharmacodynamics was also evaluated in tumor (4T1) bearing mice after intravenous injection. In vitro release experiments showed that Cur@HFn is pH sensitive and shows sustained drug release under slightly acidic conditions. Compared with Cur, Cur@HFn has stronger cytotoxicity, cellular uptake, and targeting performance. Our study supported that Cur@HFn has a higher in vivo therapeutic effect and lower systemic toxicity. The safety evaluation results indicated that Cur@HFn has no hematotoxicity, hepatotoxicity, and nephrotoxicity. The findings of the present study showed that the Cur@HFn has been successfully prepared and has potential application value in the treatment of breast cancer.

show abstract

Theranostic potential of biodegradable polymeric nanoparticles with paclitaxel and curcumin against breast carcinoma

Abstract: Self-assembled theranostic hybrid nanoparticles containing dual drugs showed a specific targeting ability for breast carcinoma, and significantly reduced the tumor size due to the synergistic effects of the dual drugs.

Cited by 18 publications

References 44 publications

Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity

Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity

In-situ forming injectable GFOGER-conjugated BMSCs-laden hydrogels for osteochondral regeneration

Selective delivery of curcumin to breast cancer cells by self-targeting apoferritin nanocages with pH-responsive and low toxicity

Contact Info

Product

Resources

About